NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

abeta,

Methylated mesenchymal patients have some of the best long term survival with DC therapy based on what Dr. Linda Liau and others have found. Mesenchymal is predominantly unmethylated but even methylation strength is not uniform. Those with hyper methylation, a small subgroup of patients, tend to be those with the best results. Proneural is predominantly methylated but a smaller subgroup than many others. Some studies have found that up to 75% or more of 3 year GBM survivors have methylated MGMT status. We see that scenario apparently being played out in this trial as well based on the data. The interesting thing to note is that the best responding patients in this trial are not all methylated or have all 3 strongest correlating factors to survival. Best wishes.